KDR and neoplasm: Targeting VEGFR1, VEGFR2, VEGFR3, PDGFRα, PDGFRβ And c-kit as a vascular endothelial growth factor receptor inhibitor, it can act directly on tumor cells as a RAF inhibitor (162, 163)